Skip to main content

Main menu

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Subscribers
    • Advertisers
    • Editorial Board
    • Special Issues 2025
  • Journal Metrics
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics

User menu

  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Anticancer Research
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics
  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Anticancer Research

Advanced Search

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Subscribers
    • Advertisers
    • Editorial Board
    • Special Issues 2025
  • Journal Metrics
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Visit us on Facebook
  • Follow us on Linkedin
Research ArticleClinical Studies

Clinical Significance of Tumor Pathology for Postoperative Survival of Patients Undergoing Surgery for Stage IV Colorectal Cancer

MITSURU ISHIZUKA, HITOSHI NAGATA, KAZUTOSHI TAKAGI, YOSHIMI IWASAKI, NORISUKE SHIBUYA and KEIICHI KUBOTA
Anticancer Research August 2012, 32 (8) 3291-3297;
MITSURU ISHIZUKA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: mm-ishizuka@umin.ac.jp
HITOSHI NAGATA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
KAZUTOSHI TAKAGI
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
YOSHIMI IWASAKI
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
NORISUKE SHIBUYA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
KEIICHI KUBOTA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Abstract

Uni- and multivariate analyses were performed in order to assess the most valuable clinical features that were associated with the overall survival of 169 patients who underwent surgery for stage IV colorectal cancer (CRC). Univariate analyses demonstrated that tumor pathology (other/tub1, 2), the proportion of neutrophils and lymphocytes, serum level of C-reactive protein and albumin, neutrophil to lymphocyte ratio, and intraoperative bleeding volume were associated with overall survival. Multivariate analysis using these seven selected features disclosed that only tumor pathology was associated with the overall survival (p<0.001). In addition, tumor pathology was able to divide not only the patients as a whole (p<0.001), but also both patients with stage IVa (p=0.007) and IVb (p=0.007), into two groups for overall survival, respectively. Tumor pathology is not only associated with the overall survival but is also able to divide both patients as a whole and those sub-classified by stage, into two independent groups before surgery.

  • Overall survival
  • stage IV colorectal cancer
  • subclass of stage IV colorectal cancer
  • tumor pathology

Although stage IV colorectal cancer (CRC) has been regarded as a lethal and final stage of the disease (1, 2), some patients are able to achieve long-term postoperative survival (3) with multidisciplinary treatments, including gold standard chemotherapy regimens such as Folinic acid (leucovorin)/ Fluorouracil (5-FU)/Irinotecan (Camptosar) (FOLFIRI) (4) or Folinic acid (leucovorin)/Fluorouracil (5-FU)/Oxaliplatin (Eloxatin) (FOLFOX) (5-7). Furthermore, recent antibody agents have improved the survival of CRC patients who receive chemotherapy (8, 9). Therefore, it is necessary to investigate the clinical features of the patients in order, to rule out those for whom the outcome is likely to be poor (10, 11).

The latest revision of the TNM Classification of Malignant Tumors (seventh edition) (http://www.onconet.kiev.ua/ru/vremennaya/TNM%207.pdf) has indicated that there are two subclasses of stage IV CRC: stage IVa (M1a) and IVb (M1b). According to the definition, IVa (M1a) is defined as metastasis confined to one organ (liver, lung, ovary, non-regional lymph nodes), whereas IVb (M1b) is defined as metastasis in more than one organ or the peritoneum.

Nevertheless, it is acceptable that this definition might not be perfect for dividing stage IV CRC patients into two groups showing a significant difference in postoperative survival, because in each group there would be two types of patients: those for whom surgery would be relatively curative, and those for whom it would be non-curative. Clearly, stage IVb CRC patients undergoing curative surgery might expect longer postoperative survival than stage IVa CRC patients who undergo non-curative surgery.

In fact, patients undergoing surgery for primary CRC and resectable small single-peritoneal disseminated nodules (curative surgery for stage IVb CRC) would expect longer postoperative survival than patients undergoing surgery for primary CRC and unresectable multiple metastatic liver tumors (non-curative surgery for stage IVa CRC). Due to this heterogeneity of operative curability, there might be stage migration within this new classification (12).

On this regard, we tried to explore the clinical features that are most closely associated with the overall survival of patients with stage IV CRC and to evaluate whether those features are able to divide such patients into two independent groups.

Patients and Methods

A retrospective review was performed using a database of patients who had undergone elective surgery for CRC. All procedures were performed by the same surgical team at the Department of Gastroenterological Surgery, Dokkyo Medical University Hospital, between March 2000 and November 2011. Among these patients, 169 were enrolled in this study. All the patients were diagnosed as having stage IV CRC, and all underwent CRC resection to evaluate the primary tumor. Therefore, patients who underwent only stoma formation and bypass-surgery because the primary tumor was unresectable were excluded, as were patients for whom data were insufficient for analysis.

Routine laboratory measurements, including the levels of tumor markers such as carcinoembryonic antigen (CEA) (upper physiological value: 5 ng/ml) (13, 14), were carried out on the day of admission. None of the patients had clinical evidence of infection or other inflammatory conditions such as obstructive colitis, and none had undergone preoperative chemotherapy or irradiation. All patients underwent preoperative colonoscopy examinations to clarify the pathological characteristics of their tumors.

Univariate analysis was performed to evaluate clinical features including age (>70* versus <70, years), sex (male* versus female), tumor site (rectum* versus colon), tumor type (3, 4, 5* versus 0, 1, 2) (invasive type/non-invasive type), number of tumors (>2* versus 1), maximum tumor size (>40* versus <40, mm), tumor pathology (other* versus tub1, tub2) (other types of carcinoma/differentiated adenocarcinoma), lymphatic invasion (presence* versus absence), venous invasion (presence* versus absence), lymph node metastasis (presence* versus absence), white blood cell (WBC) count, neutrophil ratio, lymphocyte ratio, monocyte ratio, platelet count (15), serum levels of C-reactive protein (CRP) (16), albumin (17) and CEA (14), body mass index (BMI) (18), subclass of stage IV CRC (VIb* versus VIa), neutrophil to lymphocyte ratio (NLR) (19), operative time and intraoperative bleeding volume, to select those features that were associated with overall survival (*reference group).

Multivariate analysis was performed using clinical features selected by univariate analysis with a p-value of <0.05.

Definition of curability. On the basis of the Japanese Classification of Colorectal Carcinoma (Japanese Society for Cancer of the Colon and Rectum, Second English Edition) (20), absence of residual tumor is diagnosed as R0, absence of residual tumor but tumor suspected at the resection margin as R1, and macroscopically evident residual tumor as R2 (20).

On the basis of this definition, operative curability is defined as: curability A (Cur A), R0 at TNM stage I, II or III; curability B (Cur B), R0 at TNM stage IV or R1 at any TNM stage; and curability C (Cur C), R2 at any TNM stage. Therefore, there is Cur B or C in patients with stage IV CRC (20).

Definition of macroscopic tumor types and pathological findings. Similarly, macroscopic tumor types are classified as: Type 0, superficial type; type 1, polypoid type; type 2, ulcerated type with a clear margin; type 3, ulcerated type with infiltration; type 4, diffusely infiltrating type; type 5, unclassified type (20).

According to these definitions, we classified patients into two disease groups: non-invasive type (0, 1, 2) and invasive type (3, 4, 5).

The pathological types of tumors are defined as: tub1, well-differentiated adenocarcinoma; tub2, moderately differentiated adenocarcinoma; por, poorly differentiated adenocarcinoma; muc, mucinous adenocarcinoma; sig, signet-ring cell carcinoma (20).

According to these definitions, we classified patients into two groups: those with differentiated adenocarcinoma (tub1, 2) and those with other types of carcinomas (por, muc and sig).

Invasion of vessels, i.e. lymphatic invasion (ly) and venous invasion (v), is diagnosed as: ly0 (v0), no invasion; ly1 (v1), minimal invasion; ly2 (v2), moderate invasion; ly3 (v3), severe invasion (20).

According to these definitions, we classified patients into two groups: those without invasion (ly0, v0) and those with invasion (ly1-3, v1-3).

Administration of chemotherapy. Most patients with stage IV disease undergoing surgery were considered for postoperative chemotherapy. Recently formulated chemotherapy regimens such as FOLFIRI (4) and FOLFOX (5-7) were introduced in our Department in January 2005, and patients who had undergone surgery before that time were orally administered anticancer drug regimens based on 5-fluorouracil as postoperative chemotherapy (21, 22).

Statistical analysis. Data are presented as the mean±standard deviation (SD). Differences between groups were analyzed using the chi-squared test and the Mann-Whitney U-test. Odds ratios with 95% confidence interval (95% C.I.) were calculated by uni- or multivariate analysis using the Cox proportional hazards model.

Kaplan-Meier analysis and log-rank test were used to compare the survival curves of the two groups. Deaths prior to November 31st 2011 were included in this analysis.

Statistical analyses were performed using the SPSS statistical software package, version 16.0 (SPSS Inc., Chicago, IL, USA), at a significance level of p<0.05.

Results

The relationships between clinical background features of the 169 patients who underwent surgery for stage IV CRC (stage IVa/IVb) are shown in Table I. There were 77 patients with stage IVa and 92 patients with stage IVb, 112 males and 57 females, 119 colon carcinomas and 50 rectal carcinomas. There were no significant inter-group differences between the clinical background features and the subclass of stage IV CRC, except for tumor type (p=0.017), lymphatic invasion (p=0.017) and operative curability (p<0.001) (chi-squared test).

Table II shows the relationship between the clinicolaboratory features in patients with stage IV CRC and the subclass of stage IV CRC. There were no significant inter-group differences between the clinical features and the subclass of stage IV CRC except for the serum levels of albumin (p=0.037), BMI (p=0.024), operative time (p<0.001) and intraoperative bleeding volume (ml) (p=0.038) (Mann-Whitney U-test).

Table III shows the results of univariate analysis. During the observation period, 96 patients died, of whom, 86 died of cancer-related disease. Univariate analysis was performed to evaluate the influence of clinical features on overall survival, but this revealed no significant features except for tumor pathology (other* versus tub1, tub2) (p<0.001), neutrophil ratio (p=0.004), lymphocyte ratio (p=0.004), the serum levels of CRP (p=0.003) and albumin (p=0.011), NLR (p=0.006) and intraoperative bleeding volume (p=0.020) (*reference group).

View this table:
  • View inline
  • View popup
  • Download powerpoint
Table I.

Relationships between clinical background features and subclass of stage IV colorectal carcinoma.

Multivariate analysis using the seven clinical features selected by univariate analyses, i.e. tumor pathology (other* versus tub1, tub2) (*reference group), neutrophil ratio, lymphocyte ratio, the serum level of CRP and albumin, NLR, and intraoperative bleeding volume to assess those most closely associated with overall survival disclosed that only tumor pathology had such an association (odds ratio 0.280; 95% CI 0.150-0.524; p<0.001) (Table IV).

The median and maximum follow-up periods for survivors were 420 and 3529 days, respectively, and the mean±SD postoperative survival period was 572±584 days. There was no significant difference in the postoperative survival period between patients with stage IVa (636±577 days) and those with VIb (518±588 days) disease (p=0.073). Similarly, Kaplan-Meier analysis and log-rank test revealed no significant difference in overall survival between these two patient groups (p=0.057) (Figure 1). On the other hand, tumor pathology was able to divide stage IV CRC patients into two independent groups (p<0.001) (Figure 2).

View this table:
  • View inline
  • View popup
  • Download powerpoint
Table II.

Values are the mean±SD. Relationships between clinicolaboratory features and subclass of stage IV colorectal carcinoma.

Subclass analyses using tumor pathology were performed for patients with stage IVa and IVb, respectively. There was a significant difference between the two groups divided by tumor pathology for both patients with stage IVa (p=0.007) (Figure 3a) and those with stage IVb (p=0.007) (Figure 3b) disease for which patients with tub1 or tub2 had significantly better survival.

Discussion

Although the recent revision of the TNM classification now divides stage IV CRC into two subgroups, i.e. stage IVa and IVb, based on the formation of metastases, including M1a and M1b, Kaplan-Meier analysis and log-rank test revealed that there was no significant difference in overall survival between these subgroups. Because stage IV is regarded as the final stage of CRC, most patients at that stage cannot expect long-term survival, even if they undergo surgical resection.

In the present study, comparison of patients with stage IVa and IVb disease revealed no significant differences in their clinical background features except for tumor type and lymphatic invasion. This suggested that invasive tumors and tumors with lymphatic invasion might have a tendency for peritoneal metastasis (23), because patients with stage IVb had a higher ratio of Cur C operations for peritoneal dissemination than did patients with stage IVa (data not shown). Similarly, patients with stage IVb had a significantly lower serum albumin level and BMI than did patients with stage IVa. Because these two clinical features reflect cachexia (24), it was obvious that patients with stage IVb were in poorer general condition than patients with stage IVa disease.

View this table:
  • View inline
  • View popup
  • Download powerpoint
Table III.

Univariate analyses in relation to overall survival.

In fact, patients with stage IVb disease had a shorter operation time and lower intraoperative bleeding volume than did patients with stage IVa disease, indicating that the degree of surgical insult would be reduced in the former patients, who included a higher proportion of Cur C cases. Therefore, the fact that there were significant differences in the above two surgical parameters between patients with stage IVa and IVb CRC is not surprising.

Among numerous clinical background features, uni- and multivariate analyses clearly demonstrated that only tumor pathology was associated with the overall survival of patients undergoing surgery for stage IV CRC. In addition, Kaplan-Meier analysis and log rank test revealed that tumor pathology was able to divide not only patient group as a whole, but also both groups of patients with stage IVa and IVb disease into two independent groups.

View this table:
  • View inline
  • View popup
  • Download powerpoint
Table IV.

Multivariate analysis in relation to overall survival.

Most patients with CRC generally have almost the same common pathological types of tumor: well-(tub1) or moderately-(tub2) differentiated adenocarcinoma (25, 26). In fact, in the present study, 88.8% (150/169) of patients had tub1 or 2 tumor pathology, and only 11.2% (19/169) had other types of tumor pathology. Therefore, tumor pathology could be a useful parameter for screening patients likely to have a poor prognosis because survival curve analyses demonstrated that patients whith a pathological type other than tub 1/2 had poorer overall survival than patients with tub1 or 2.

Figure 1.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 1.

Relationship between subclasses of stage IV (groups stage VIa and VIb) and overall survival in patients undergoing surgery for stage IV colorectal carcinoma.

Figure 2.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 2.

Relationship between tumor pathology (groups tub 1, 2, and other) and overall survival in patients undergoing surgery for stage IV colorectal carcinoma.

Although the final diagnosis of tumor pathology should be based on the surgically resected specimen, most biopsy specimens are easily obtained by colonoscopy before surgery. Therefore, tumor pathology determined from such specimens, would be valuable in determining before surgery whether or not patients with stage IV CRC would have a poor prognosis.

In addition, because patients diagnosed as having stage IV CRC without the common tumor pathological types would definitively have a poorer prognosis than stage IV patients with the common tumor pathological types, such patients would require systemic chemotherapy before surgery to improve their chance of survival (27-29). However, because most of the current study patients had undergone multidisciplinary treatments after surgery, it might be difficult to improve the overall survival of these patients even if preoperative intensive treatment were to be implemented.

Figure 3.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 3.

Relationship between tumor pathology (groups tub 1, 2, and other) and overall survival in patients undergoing surgery for stage IVa colorectal carcinoma (CRC) (M1a) (a) and for stage IVb CRC (M1b) (b).

Therefore, a prospective randomized trial would be required in order to clarify the effect of preoperative systemic chemotherapy (27) for such patients with a poor prognosis (1, 2), because in the present study no patients with stage IV CRC without the common types of tumor pathology survived for more than 1,000 days after surgery.

Thus, in comparison with the TNM subclasses of stage IV CRC (IVa/IVb), tumor pathology is a significant feature, allowing for the preoperative division of patients with stage IV CRC into two subclasses, based on their expected postoperative survival.

Acknowledgements

We received no funding/grant support for this study.

Footnotes

  • Conflicts of Interest

    We have no conflicts of interest to declare.

  • Received April 15, 2012.
  • Revision received June 21, 2012.
  • Accepted June 22, 2012.
  • Copyright© 2012 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved

References

  1. ↵
    1. Konyalian VR,
    2. Rosing DK,
    3. Haukoos JS,
    4. Dixon MR,
    5. Sinow R,
    6. Bhaheetharan S,
    7. Stamos MJ,
    8. Kumar RR
    : The role of primary tumour resection in patients with stage IV colorectal cancer. Colorectal Dis 9: 430-437, 2007.
    OpenUrlCrossRefPubMed
  2. ↵
    1. Verhoef C,
    2. de Wilt JH,
    3. Burger JW,
    4. Verheul HM,
    5. Koopman M
    : Surgery of the primary in stage IV colorectal cancer with unresectable metastases. Eur J Cancer 47: 61-66, 2011.
    OpenUrl
  3. ↵
    1. Hotta T,
    2. Takifuji K,
    3. Arii K,
    4. Yokoyama S,
    5. Matsuda K,
    6. Higashiguchi T,
    7. Tominaga T,
    8. Oku Y,
    9. Yamaue
    : Potential predictors of long-term survival after surgery for patients with stage IV colorectal cancer. Anticancer Res 26: 1377-1383, 2006.
    OpenUrlAbstract/FREE Full Text
  4. ↵
    1. Saltz LB,
    2. Niedzwiecki D,
    3. Hollis D,
    4. Goldberg RM,
    5. Hantel A,
    6. Thomas JP,
    7. Fields AL,
    8. Mayer RJ
    : Irinotecan fluorouracil plus leucovorin is not superior to fluorouracil plus leucovorin alone as adjuvant treatment for stage III colon cancer: results of CALGB 89803. J Clin Oncol 25: 3456-3461, 2007.
    OpenUrlAbstract/FREE Full Text
  5. ↵
    1. de Gramont A,
    2. Figer A,
    3. Seymour M,
    4. Homerin M,
    5. Hmissi A,
    6. Cassidy J,
    7. Boni C,
    8. Cortes-Funes H,
    9. Cervantes A,
    10. Freyer G,
    11. Papamichael D,
    12. Le Bail N,
    13. Louvet C,
    14. Hendler D,
    15. de Braud F,
    16. Wilson C,
    17. Morvan F,
    18. Bonetti
    : Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 18: 2938-2947, 2000.
    OpenUrlAbstract/FREE Full Text
    1. Goldberg RM,
    2. Sargent DJ,
    3. Morton RF,
    4. Fuchs CS,
    5. Ramanathan RK,
    6. Williamson SK,
    7. Findlay BP,
    8. Pitot HC,
    9. Alberts SR
    : A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 22: 23-30, 2004.
    OpenUrlAbstract/FREE Full Text
  6. ↵
    1. Andre T,
    2. Boni C,
    3. Mounedji-Boudiaf L,
    4. Navarro M,
    5. Tabernero J,
    6. Hickish T,
    7. Topham C,
    8. Zaninelli M,
    9. Clingan P,
    10. Bridgewater J,
    11. Tabah-Fisch I,
    12. de Gramont A
    : Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 350: 2343-2351, 2004.
    OpenUrlCrossRefPubMed
  7. ↵
    1. Hurwitz H,
    2. Fehrenbacher L,
    3. Novotny W,
    4. Cartwright T,
    5. Hainsworth J,
    6. Heim W,
    7. Berlin J,
    8. Baron A,
    9. Griffing S,
    10. Holmgren E,
    11. Ferrara N,
    12. Fyfe G,
    13. Rogers B,
    14. Ross R,
    15. Kabbinavar F
    : Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350: 2335-2342, 2004.
    OpenUrlCrossRefPubMed
  8. ↵
    1. Van Cutsem E,
    2. Kohne CH,
    3. Hitre E,
    4. Zaluski J,
    5. Chang Chien CR,
    6. Makhson A,
    7. D'Hasens G,
    8. Pinter T,
    9. Lim R,
    10. Bodoky G,
    11. Roh JK,
    12. Folprecht G,
    13. Ruff P,
    14. Stroh C,
    15. Tejpar S,
    16. Schlichting M,
    17. Nippgen J,
    18. Rougier P
    : Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 360: 1408-1417, 2009.
    OpenUrlCrossRefPubMed
  9. ↵
    1. Katoh H,
    2. Yamashita K,
    3. Kokuba Y,
    4. Satoh T,
    5. Ozawa H,
    6. Hatate K,
    7. Ihara A,
    8. Nakamura T,
    9. Onosato W,
    10. Watanabe M
    : Surgical resection of stage IV colorectal cancer and prognosis. World J Surg 32: 1130-1137, 2008.
    OpenUrlPubMed
  10. ↵
    1. Hotokezaka M,
    2. Jimi S,
    3. Hidaka H,
    4. Ikeda T,
    5. Uchiyama S,
    6. Nakashima S,
    7. Tsuchiya K,
    8. Chijiiwa K
    : Factors influencing outcome after surgery for stage IV colorectal cancer. Surg Today 38: 784-789, 2008.
    OpenUrlPubMed
  11. ↵
    1. Nitsche U,
    2. Maak M,
    3. Schuster T,
    4. Kunzli B,
    5. Langer R,
    6. Slotta-Huspenina J,
    7. Janssen KP,
    8. Friess H,
    9. Rosenberg R
    : Prediction of prognosis is not improved by the seventh and latest edition of the TNM Classification for Colorectal Cancer in a single-center collective. Ann Surg 254: 793-800, 2011.
    OpenUrlCrossRefPubMed
  12. ↵
    1. Park IJ,
    2. Choi GS,
    3. Lim KH,
    4. Kang BM,
    5. Jun SH
    : Serum carcinoembryonic antigen monitoring after curative resection for colorectal cancer: clinical significance of the preoperative level. Ann Surg Oncol 16: 3087-3093, 2009.
    OpenUrlCrossRefPubMed
  13. ↵
    1. Wang JY,
    2. Lu CY,
    3. Chu KS,
    4. Ma CJ,
    5. Wu DC,
    6. Tsai HL,
    7. Yu FJ,
    8. Hsieh JS
    : Prognostic significance of pre- and postoperative serum carcinoembryonic antigen levels in patients with colorectal cancer. Eur Surg Res 39: 245-250, 2007.
    OpenUrlCrossRefPubMed
  14. ↵
    1. Sasaki K,
    2. Kawai K,
    3. Tsuno NH,
    4. Sunami E,
    5. Kitayama J
    : Impact of preoperative thrombocytosis on the survival of patients with primary colorectal cancer. World J Surg 36: 192-200, 2012.
    OpenUrlCrossRefPubMed
  15. ↵
    1. Ishizuka M,
    2. Kita J,
    3. Shimoda M,
    4. Rokkaku K,
    5. Kato M,
    6. Sawada T,
    7. Kubota K
    : Systemic inflammatory response predicts postoperative outcome in patients with liver metastases from colorectal cancer. J Surg Oncol 100: 38-42, 2009.
    OpenUrlCrossRefPubMed
  16. ↵
    1. Elahi MM,
    2. McMillan DC,
    3. McArdle CS,
    4. Angerson WJ,
    5. Sattar N
    : Score based on hypoalbuminemia and elevated C-reactive protein predicts survival in patients with advanced gastrointestinal cancer. Nutr Cancer 48: 171-173, 2004.
    OpenUrlCrossRefPubMed
  17. ↵
    1. Ishizuka M,
    2. Kubota K,
    3. Kita J,
    4. Shimoda M,
    5. Kato M,
    6. Sawada T
    : Underweight patients show an increased rate of postoperative death after surgery for hepatocellular carcinoma. J Surg Oncol 104: 809-813, 2011.
    OpenUrlPubMed
  18. ↵
    1. Shimada H,
    2. Takiguchi N,
    3. Kainuma O,
    4. Soda H,
    5. Ikeda A,
    6. Cho A,
    7. Miyazaki A,
    8. Gunji H,
    9. Yamamoto H,
    10. Nagata M
    : High preoperative neutrophil-lymphocyte ratio predicts poor survival in patients with gastric cancer. Gastric Cancer 13: 170-176, 2010.
    OpenUrlCrossRefPubMed
  19. ↵
    1. Watanabe T,
    2. Itabashi M,
    3. Shimada Y,
    4. Tanaka S,
    5. Ito Y,
    6. Ajioka Y,
    7. Hamaguchi T,
    8. Hyodo I,
    9. Igarashi M,
    10. Ishida H,
    11. Ishiguro M,
    12. Kanemitsu Y,
    13. Kokudo N,
    14. Muro K,
    15. Ochiai A,
    16. Oguchi M,
    17. Ohkura Y,
    18. Saito Y,
    19. Sakai Y,
    20. Ueno H,
    21. Yoshino T,
    22. Fujimori T,
    23. Koinuma N,
    24. Morita T,
    25. Nishimura G,
    26. Sakata Y,
    27. Takahashi K,
    28. Takiuchi H,
    29. Tsuruta O,
    30. Yamaguchi T,
    31. Yoshida M,
    32. Yamaguchi N,
    33. Kotake K,
    34. Sugihara K,
    35. Japanese Society for Cancer of the Colon and Rectum
    : Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2010 for the treatment of colorectal cancer. Int J Clin Oncol 17: 1-29, 2012.
    OpenUrlCrossRefPubMed
  20. ↵
    1. Tanaka F
    : UFT (tegafur and uracil) as postoperative adjuvant chemotherapy for solid tumors (carcinoma of the lung, stomach, colon/rectum, and breast): clinical evidence, mechanism of action, and future direction. Surg Today 37: 923-943, 2007.
    OpenUrlCrossRefPubMed
  21. ↵
    1. Koda K,
    2. Miyazaki M,
    3. Sarashina H,
    4. Suwa T,
    5. Saito N,
    6. Suzuki M,
    7. Ogawa K,
    8. Watanabe S,
    9. Kodaira S,
    10. Nakazato H
    : A randomized controlled trial of postoperative adjuvant immunochemotherapy for colorectal cancer with oral medicines. Int J Oncol 23: 165-172, 2003.
    OpenUrlPubMed
  22. ↵
    1. Yang SH,
    2. Lin JK,
    3. Lai CR,
    4. Chen CC,
    5. Li AF,
    6. Liang WY,
    7. Jiang JK
    : Risk factors for peritoneal dissemination of colorectal cancer. J Surg Oncol 87: 167-173, 2004.
    OpenUrlCrossRefPubMed
  23. ↵
    1. Kotler DP
    : Cachexia. Ann Intern Med 133: 622-634, 2000.
    OpenUrlCrossRefPubMed
  24. ↵
    1. Ponz de Leon M,
    2. Di Gregorio C
    : Pathology of colorectal cancer. Dig Liver Dis 33: 372-388, 2001.
    OpenUrlCrossRefPubMed
  25. ↵
    1. Tanaka T
    : Colorectal carcinogenesis: Review of human and experimental animal studies. J Carcinog 8: 1-19, 2009.
    OpenUrlPubMed
  26. ↵
    1. Nordlinger B,
    2. Sorbye H,
    3. Glimelius B,
    4. Poston GJ,
    5. Schlag PM,
    6. Rougier P,
    7. Bechstein WO,
    8. Prmrose JN,
    9. Walpole ET,
    10. Finch-Jones M,
    11. Jaeck D,
    12. Mirza D,
    13. Parks RW,
    14. Collette L,
    15. Praet M,
    16. Bethe U,
    17. Van Cutsem E,
    18. Scheithauer W,
    19. Gruenberger T
    : Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial. Lancet 371: 1007-1016, 2008.
    OpenUrlCrossRefPubMed
    1. Adam R,
    2. Delvart V,
    3. Pascal G,
    4. Valeanu A,
    5. Castaing D,
    6. Azoulay D,
    7. Giacchetti S,
    8. Paule B,
    9. Kunstlinger F,
    10. Ghemard O,
    11. Levi F,
    12. Bismuth H
    : Rescue surgery for unresectable colorectal liver metastases downstaged by chemotherapy: A model to predict long-term survival. Ann Surg 240: 644-657, 2004.
    OpenUrlCrossRefPubMed
  27. ↵
    1. Folprecht G,
    2. Grothey A,
    3. Alberts S,
    4. Raab HR,
    5. Kohne CH
    : Neoadjuvant treatment of unresectable colorectal liver metastases: Correlation between tumour response and resection rates. Ann Oncol 16: 1311-1319, 2005.
    OpenUrlCrossRefPubMed
PreviousNext
Back to top

In this issue

Anticancer Research: 32 (8)
Anticancer Research
Vol. 32, Issue 8
August 2012
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
  • Back Matter (PDF)
  • Ed Board (PDF)
  • Front Matter (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Anticancer Research.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Clinical Significance of Tumor Pathology for Postoperative Survival of Patients Undergoing Surgery for Stage IV Colorectal Cancer
(Your Name) has sent you a message from Anticancer Research
(Your Name) thought you would like to see the Anticancer Research web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
8 + 5 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.
Citation Tools
Clinical Significance of Tumor Pathology for Postoperative Survival of Patients Undergoing Surgery for Stage IV Colorectal Cancer
MITSURU ISHIZUKA, HITOSHI NAGATA, KAZUTOSHI TAKAGI, YOSHIMI IWASAKI, NORISUKE SHIBUYA, KEIICHI KUBOTA
Anticancer Research Aug 2012, 32 (8) 3291-3297;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Reprints and Permissions
Share
Clinical Significance of Tumor Pathology for Postoperative Survival of Patients Undergoing Surgery for Stage IV Colorectal Cancer
MITSURU ISHIZUKA, HITOSHI NAGATA, KAZUTOSHI TAKAGI, YOSHIMI IWASAKI, NORISUKE SHIBUYA, KEIICHI KUBOTA
Anticancer Research Aug 2012, 32 (8) 3291-3297;
Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Patients and Methods
    • Results
    • Discussion
    • Acknowledgements
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • Clinical Outcomes of Metastasis-directed Therapy for Oligo-metastatic Prostate Cancer Diagnosed Using PSMA-PET/CT or Whole-body MRI
  • Blood Concentrations of Osimertinib and Its Active Metabolites: Impact on Treatment Efficacy and Safety
  • Randomized Study of Short-time Continuous Saline Irrigation After Transurethral Resection in Non-muscle Invasive Bladder Cancer
Show more Clinical Studies

Similar Articles

Anticancer Research

© 2025 Anticancer Research

Powered by HighWire